Autolus Therapeutics (AUTL) Stock Price, News & Analysis

Company Overview

Autolus Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of next-generation programmed T cell therapies for the treatment of cancer. The company’s proprietary CAR T cell platform leverages advanced gene editing and synthetic biology to create T cells with enhanced targeting, safety switches and controllable activity. Its lead programs focus on haematological malignancies, including acute lymphoblastic leukemia and non-Hodgkin lymphoma, with several candidates in ongoing Phase 1 and Phase 2 clinical trials.

Founded in 2014 by a team of immunologists and cell therapy pioneers from University College London and the University of Oxford, Autolus has rapidly built a robust pipeline of autologous T cell products. Key assets feature modular receptor designs and split signaling pathways aimed at improving durability of response and reducing off-tumor toxicity. In addition to its lead CD19- and CD22-targeting therapies, the company is advancing dual-targeted approaches and bispecific constructs intended to address antigen escape and broaden therapeutic applicability.

Headquartered in London, Autolus operates research and development facilities in the United Kingdom and the United States, including a state-of-the-art cell engineering and manufacturing center in Pennsylvania. This transatlantic footprint supports both early-stage discovery work and late-stage clinical manufacturing under current good manufacturing practice (cGMP). The company collaborates with academic institutions and clinical centers of excellence across Europe and North America to conduct multi-site trials and accelerate patient access.

Under the leadership of Chief Executive Officer Dr. Christian Itin and an executive team with deep expertise in cell therapy development and commercial operations, Autolus is focused on delivering innovative T cell medicines to patients with high-unmet-need cancers. The company’s strategic priorities include advancing its clinical portfolio, scaling manufacturing capabilities and establishing global partnerships to expand the reach of its modular CAR T technology.

Key Stats

• Today's Range: $2.39 to $2.56
• 50-Day Range: $1.22 to $2.65
• 52-Week Range: $1.11 to $5.00
• Volume: 952,057 shs
• Average Volume: 1.56 million shs
• Market Capitalization: $649.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.32
• Consensus Rating: Buy

Autolus Therapeutics Stock Analysis - MarketRank™

Autolus Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 531st out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Autolus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Autolus Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Autolus Therapeutics are expected to grow in the coming year, from ($0.94) to ($0.83) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Autolus Therapeutics is -2.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Autolus Therapeutics is -2.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Autolus Therapeutics has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.91% of the float of Autolus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Autolus Therapeutics has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Autolus Therapeutics has recently increased by 7.55%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Autolus Therapeutics does not currently pay a dividend.

Dividend Growth

Autolus Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.91% of the float of Autolus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Autolus Therapeutics has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Autolus Therapeutics has recently increased by 7.55%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.71

News Sentiment

Autolus Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.95 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Autolus Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 4 people have searched for AUTL on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.

MarketBeat Follows

8 people have added Autolus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Autolus Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

25.70% of the stock of Autolus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

72.83% of the stock of Autolus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AUTL Stock Analysis - Frequently Asked Questions

How have AUTL shares performed this year?

Autolus Therapeutics' stock was trading at $2.35 at the start of the year. Since then, AUTL shares have increased by 3.8% and is now trading at $2.44.

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) posted its earnings results on Thursday, May, 8th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.02. The firm earned $8.98 million during the quarter, compared to analyst estimates of $1.59 million.
Read the conference call transcript.

When did Autolus Therapeutics IPO?

Autolus Therapeutics (AUTL) raised $125 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

Who are Autolus Therapeutics' major shareholders?

Top institutional shareholders of Autolus Therapeutics include Atle Fund Management AB (0.42%), Perpetual Ltd (0.31%), Avanza Fonder AB (0.02%) and Wealth Effects LLC (0.01%).

How do I buy shares of Autolus Therapeutics?

Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Autolus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Autolus Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and CymaBay Therapeutics (CBAY).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/17/2025
• Next Earnings (Estimated): 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AUTL
• CIK: 1730463
• Web: www.autolus.com
• Phone: 442038296230
• Fax: N/A
• Employees: 330
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Autolus Therapeutics: $9.32
• High Price Target: $13.00
• Low Price Target: $6.00
• Potential Upside/Downside: +282.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$220.66 million
• Net Margins: N/A
• Pretax Margin: -2,600.95%
• Return on Equity: -52.82%
• Return on Assets: -29.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.24
• Quick Ratio: 9.02

Sales & Book Value

• Annual Sales: $10.12 million
• Price / Sales: 64.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.61 per share
• Price / Book: 1.52

Miscellaneous

• Outstanding Shares: 266,140,000
• Free Float: 197,743,000
• Market Cap: $649.38 million
• Optionable: Optionable
• Beta: 1.81